Evidence map›Paper›PMID 35496786›Full record

ArticleSTAR protocols2022

Protocol for

Elizabeth V Minten, David S Yu

Open access · goldAbstract read
In one paragraph

Article in STAR protocols, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Elizabeth V MintenDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
David S YuDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Dana-Farber Cancer Institute · USEmory University · US

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Training Program in Biochemistry, Cell and Molecular BiologyT32GM008367 · NIGMS · EMORY UNIVERSITY · PI BOISE, LAWRENCE H., CORBETT, ANITA H. · 1990 to 2019
$5.6M
Mechanisms of SIRT2 Function in the Replication Stress ResponseR01CA178999 · NCI · EMORY UNIVERSITY · PI YU, DAVID SUNG-WEN · 2013 to 2023
$3.5M
Elucidating SAMHD1 in DNA Double-Strand Break Repair (Supplement)R01CA254403 · NCI · EMORY UNIVERSITY · PI KIM, BAEK, YU, DAVID SUNG-WEN · 2020 to 2024
$2.9M
Elucidating control of BRCA1 by SIRT2 in DNA double-strand break repairF31CA225124 · NCI · EMORY UNIVERSITY · PI MINTEN, ELIZABETH · 2018 to 2020
$94k
NCI NIH HHS F31 CA225124NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA178999NCI NIH HHS R01 CA254403NIGMS NIH HHS T32 GM008367
6 · The paper itself

Abstract

Lysine acetylation is an important post-translational modification that is used in multiple cellular pathways, such as the regulation of gene expression at the histone level. The purpose of this assay is to test for putative substrates of class III deacetylases using an

Indexed as

LysineProtein Processing, Post-TranslationalAcetylationAcetyltransferasesHistonesAcetyltransferasesHistonesLysineCancerCell-based AssaysProtein BiochemistryProtein expression and purification

Identifiers

PMID35496786
PMCPMC9038758
OpenAlexW4223925394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.